Results 91 to 100 of about 15,930 (153)

Response to: "Proton-pump inhibitor use in combination with a CDK4/6 inhibitor: is formulation the issue?" [PDF]

Oncologist
Chen BF, Huang CC.
europepmc   +1 more source

First-Line Palbociclib/Letrozole Versus Ribociclib/Letrozole in Postmenopausal HR-Positive/HER2-Negative Metastatic Breast Cancer: A Retrospective Real-World Study and an Exploratory Composite Clinical-Inflammatory Risk Score. [PDF]

Medicina (Kaunas)
Tohumcuoğlu M, Yetişir AE, Cinkara ZU, Türker M, Düşgün A, Mirili C, Tazeoğlu D, Köşeci T, Oğul A, Büyükşimşek M.   +9 more
europepmc   +1 more source

A Systematic Literature Review of the Effectiveness of CDK 4/6 Inhibitors for First-Line Treatment of HR+/HER2- Advanced/Metastatic Breast Cancer: A Comparison of Real-World Evidence. [PDF]

Cancers (Basel)
Pluard T, Grinda T, Dienstmann R, Thill M, Korytowsky B, Chen C, Portuhay S, Salvo-Halloran EM, Samjoo IA, Harbeck N.   +9 more
europepmc   +1 more source

Palbociclib in combination with dexamethasone, bortezomib, and doxorubicin for pediatric relapsed acute lymphoblastic leukemia. [PDF]

Blood Neoplasia
Srinivasan SG, Kamens JL, Marks LJ, Balagtas JMS, Rubnitz JE, Gruber TA.   +5 more
europepmc   +1 more source

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer. [PDF]

Cancer Res
Juric D, Islam KN, Gkotinakou IM, Zheng A, Lee H, Saxena S, Kreuzer J, Morris R, McGrath CG, Sakhtemani R, Chevalier NJ, Kehlmann AM, Stavridi AM, Tajmir S, Stanzione M, Zaniewski EF, Mahan S, Hodel K, Meyers M, Sampath S, Schmedt C, Sampath SC, Lin TT, Liu F, VanArsdale T, Isakoff SJ, Comander A, Kim JS, Wander SA, Knudsen ES, Witkiewicz AK, Zou L, Hata AN, Lawrence MS, Haas W, Varkaris A, Sanidas I.   +36 more
europepmc   +1 more source

Palbociclib targets β-catenin for degradation and synergizes with KRAS or ERK5 inhibition in colorectal cancer preclinical models. [PDF]

J Transl Med
Villa M, Malighetti F, Villa AM, Cordani N, Aroldi A, Zambon A, Ramazzotti D, Mologni L.   +7 more
europepmc   +1 more source

Proton-pump inhibitor use in combination with a CDK4/6 inhibitor: is formulation the issue? [PDF]

Oncologist
Polwart C.
europepmc   +1 more source

CDK4/6 Inhibitors in Breast Cancer Therapy: Mechanisms, Resistance, and Emerging Opportunities. [PDF]

Target Oncol
Chinea L, Hauer C, Pal K, Chang HL, Chan IS.   +4 more
europepmc   +1 more source

<i>CDK4/6</i> Inhibitors in Breast Cancer: Clinical Applications, Translational Insights, and Future Directions. [PDF]

Cancers (Basel)
Guan M, Hao H.
europepmc   +1 more source

Comparative safety signal prioritization of CDK4/6 inhibitors in breast cancer: a FAERS pharmacovigilance, machine learning, and clinical contextualization study. [PDF]

Front Pharmacol
Fan L, Liu S, Tang Y, Han X, Zhang Z, Su C, Sui Z, Zhao W.   +7 more
europepmc   +1 more source